StockData
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. (MEDP) company profile

MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 22, 2026Score 14/3042% above fair value
$653.09+4.89 (+0.75%)

Close on Nov 17, 2026Market cap $18.27BP/E 36.2Yield –

About Medpace

Services-Commercial Physical & Biological Research, SIC 8731

Medpace Holdings, Inc. is a clinical contract research organization that provides outsourced clinical development services across Phase I through Phase IV trials. Its offerings serve biotechnology, pharmaceutical, and medical device companies, focusing especially on small and mid-sized biopharmaceutical developers. The company provides medical study design, trial execution via its proprietary ClinTrak software, patient recruitment, regulatory compliance, biometrics, pharmacovigilance, and quality assurance. Additionally, it provides specialized laboratory support through central, bioanalytical, and core imaging and cardiovascular facilities, alongside research clinics that evaluate therapeutics in healthy volunteers and targeted patient groups.

Medpace maintains an international presence with approximately 6,200 employees distributed across 46 countries worldwide. Its laboratory network spans locations in Cincinnati, Ohio; Leuven, Belgium; Shanghai, China; and Singapore. In addition, the company's dedicated bioanalytical laboratory and early-phase clinical trial facilities operate from its central research campus located in Cincinnati, Ohio, where key corporate activities are centered.

Summary of the business section of Medpace's latest annual report, written by StockData.

Company profile

Company

Legal name
Medpace Holdings, Inc.
Founded
1992
Headquarters
Cincinnati, OH
Address
5375 Medpace Way 45227
Phone
(513) 579-9911
Employees
6,200, Dec 31, 2025
Industry
Services-Commercial Physical & Biological Research
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Cincinnati, Ohio

Stock & identifiers

Ticker
MEDP
Exchange
Nasdaq
IPO date
Aug 11, 2016
Shares outstanding
28M, Oct 16, 2026
Public float
$7.00B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1668397
CUSIP
58506Q109
ISIN
US58506Q1094
FIGI
BBG0065B7K59
Share class FIGI
BBG0065B7K40
LEI
549300H8TYEUVTW14A54
EIN
32-0434904

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
August J. TroendlePresident & CEO, Director5,071,244
Stephen P. EwaldGeneral Counsel & Corp. Secy.19,098
Susan E. BurwigExec. VP, Operations54,012
Kevin M. BradyCFO & Treasurer12,830
Brad W. HansmanExec. VP, Operations697
Jesse J. GeigerPresident46,707
Robert O. KraftDirector987
Cornelius P. McCarthy IIIDirector12,303
Brian T. CarleyDirector27,861
Fred B. Davenport JrDirector11,259
Dani S. ZanderDirector–
Femida H. Gwadry-SridharDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$11.44M$11.67M$2.20M$403$99
FY2024$8.60M$17.71M$4.18M$239$81
FY2023$1.65M$9.26M$918.63K$220$82
FY2022$1.89M$12.89M$1.04M$153$77
FY2021$5.95M$7.75M$1.97M$156$96
FY2020$4.14M$5.99M$1.79M$166$130

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
August J. Troendle
Chief Executive Officer
$937.42K$492.35K$10.00M$14.00K$11.44M+33%
Kevin M. Brady
Chief Financial Officer and Treasurer
$459.70K$172.45K$1.00M$14.00K$1.65M-53%
Jesse J. Geiger
President
$641.67K$240.70K$1.50M$14.00K$2.40M-49%
Susan E. Burwig
Executive Vice President, Operations
$710.42K$497.40K$1.50M$15.92K$2.72M-44%
Stephen P. Ewald
General Counsel and Corporate Secretary
$591.51K$414.15K$1.00M$14.00K$2.02M-45%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Aug 11, 2016
Offer price
$23.00
Securities offered
7,000,000
Gross proceeds
$161.00M
Exchange
Nasdaq
First trading day
Aug 11, 2016
First-day close
$27.79+20.8%
Lock-up ends (est.)
Feb 7, 2017

“The initial public offering price is $23.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025 we had approximately 6,200 employees located across 46 countries.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?